An interventional study of Prolonged Fasting Intervention and EDUCATION CONTROL in Cancer Prevention, Weight Loss and Smoldering Waldenstrom Macroglobulinemia(WM), sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Fasting with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Fasting · United States.
Among the 95 studies in Fasting with a site in United States, this one is the 63rd largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2023, is one of 59 with no phase, and was the 75th registered.
392 studies on the registry are indexed under Fasting; 63 are open to participants now.
Browse Fasting studies →19 of the 95 studies in Fasting with a site in United States are open now. Recruiting first, the newest first:
University of California, San Diego · Sites in United States
Ages 18–75
University of Illinois at Chicago · Sites in United States
Ages 25–99 · Women only
Ayal A. Aizer, MD · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
University of California, San Diego · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 45 across 311 interventional studies indexed under Fasting.
Median enrollment 39 across the 85 interventional studies, 42 across the 10 observational. Of the 68 that completed or were terminated, 18 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 95 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Dana-Farber Cancer Institute has 1 study filed under Fasting — fewer than ten, so there is no comparison to draw.
8 of the studies in Fasting with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387445University of Illinois at ChicagoFeasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer. | 2026-12-31 |
| NCT04893226Julie PendergastCircadian Rhythms in Postmenopausal Women | 2027-01-31 |
| NCT06884059University of California, San DiegoTime Restricted Eating in Patients With Microalbuminuria | 2027-02 |
| NCT05545306National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure | 2027-02-02 |
| NCT03523377Memorial Sloan Kettering Cancer CenterOvernight Fasting After Completion of Therapy: The OnFACT Study | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Fasting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer.
Participants will be randomized into the following two groups:
The purpose of this research study is to learn if fasting for a prolonged period of time could be used in the future to help improve body composition and prevent blood cancer in overweight and obese individuals with MGUS, SMM, and SWM. Multiple myeloma is a cancer of the plasma cells, which is an important part of the immune system. Participants with active multiple myeloma generally require treatment. There are currently no approved therapies or prevention strategies for smoldering multiple myeloma or monoclonal gammopathy of undetermined significance.
The National Cancer Institute of the National Institutes of Health is supporting this research study by providing funding.
This research study is a 4-month randomized trial of prolonged nightly fasting (PROFAST). It is expected that about 40 people will take part in this research study. The total study duration is 4 months.
Participants in the study will be randomized, in equal numbers to either the nightly fasting intervention group or a control group.
392 studies on the registry are indexed under Fasting; 63 are open to participants now.
This study's enrollment of 23 is below the median of 45 across 311 interventional studies indexed under Fasting.
Browse Fasting studies →Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Compared within Fasting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times they record via the text messaging system. The text messaging system will be used throughout the duration of the study.
Behavioral: Prolonged Fasting Intervention
For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study
Behavioral: EDUCATION CONTROL
promote a 14-hour fast during the nighttime hours
introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
Changes in Body Composition (% Body Fat)
assessed via whole body DXA scans
Time frame: baseline to 4-months
M-Protein Change by Serum Protein Electrophoresis and Serum Free Light Chain Assay
Monoclonal (M-)proteins produced in excess by an abnormal clonal proliferation of plasma (MM) cells that can be measured in the serum using Serum Protein Electrophoresis (SPEP) and the Serum Free Light Chain Assay.
Time frame: baseline to 4-months
(M-)Protein Concentrations/Light Chains Change by Mass Spectrometry
Time frame: Baseline to 4-months
Changes in Bone Marrow Adiposity
Time frame: Baseline to 4-months
Changes in Plasma Metabolites Measured by Liquid Chromatography-mass Spectrometry
Time frame: Baseline to 4-months
| Milestone | PROLONGED FASTING INTERVENTION | EDUCATION CONTROL |
|---|---|---|
| Started | 11 | 12 |
| Completed | 10 | 10 |
| Not completed | 1 | 2 |
assessed via whole body DXA scans
| Mean Raw Change % Fat | PROLONGED FASTING INTERVENTION | EDUCATION CONTROL |
|---|---|---|
| Changes in Body Composition (% Body Fat) | -1.62 ± 2.42 | -0.59 ± 2.30 |
Monoclonal (M-)proteins produced in excess by an abnormal clonal proliferation of plasma (MM) cells that can be measured in the serum using Serum Protein Electrophoresis (SPEP) and the Serum Free Light Chain Assay.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PROLONGED FASTING INTERVENTION | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| EDUCATION CONTROL | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Age, Continuous(years) | PROLONGED FASTING INTERVENTION | EDUCATION CONTROL | Total |
|---|---|---|---|
| Mean | 68.2 (51.8 to 84.4) | 65.6 (49.8 to 77.4) | 66.9 (49.8 to 84.4) |
| Sex: Female, Male(Participants) | PROLONGED FASTING INTERVENTION | EDUCATION CONTROL | Total |
|---|---|---|---|
| Female | 3 | 5 | 8 |
| Male | 8 | 7 | 15 |
| Race/Ethnicity, Customized(Participants) | PROLONGED FASTING INTERVENTION | EDUCATION CONTROL | Total |
|---|---|---|---|
| Race (white) — White | 10 | 10 | 20 |
| Race (white) — Missing | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2023 to primary completion in Aug 2025, 28 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 144 non-industry interventional studies with no phase under Fasting, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 40. This study's 28 months is above that.
Counting every sponsor, half of 149 studies reached it within 19 months; a quarter within 6 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →